신경병증성 통증 치료 시장 : 세계 예측(2026-2032년)

The Neuropathy Pain Treatment Market is projected to grow by USD 21.18 billion at a CAGR of 12.08% by 2032.

Neuropathy pain treatment is gaining strategic importance as diabetes, cancer survivorship, autoimmune disorders, infections, traumatic nerve injury, and aging populations increase the global burden of peripheral neuropathic pain. Clinically, neuropathic pain is characterized by burning, shooting, tingling, electric-shock sensations, allodynia, and hyperalgesia, often resulting from damage or dysfunction in the somatosensory nervous system. Treatment pathways commonly combine pharmacologic therapies such as anticonvulsants, antidepressants, topical analgesics, and selected opioid-sparing approaches with interventional procedures, neuromodulation, physical rehabilitation, psychological support, glycemic control, nutritional correction, and management of underlying disease causes.

The treatment landscape is being shaped by rising diagnosis of diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, postherpetic neuralgia, radiculopathy, trigeminal neuralgia, and neuropathy linked to HIV, alcohol use, vitamin deficiencies, and chronic kidney disease. Health systems are increasingly emphasizing evidence-based, multidisciplinary pain management because persistent neuropathic pain is associated with sleep disruption, reduced mobility, depression, anxiety, work impairment, and higher healthcare utilization. For industry stakeholders, the central opportunity lies in improving durable pain relief while reducing adverse effects, polypharmacy, opioid exposure, and treatment discontinuation. Clinical guidelines and payer policies continue to favor therapies with proven efficacy, safety, and functional outcomes, while digital health and artificial intelligence are beginning to support earlier identification, treatment optimization, and remote monitoring of chronic neuropathic pain.

Transformative Shifts in the Neuropathy Pain Treatment Landscape

The neuropathy pain treatment landscape is undergoing a major transition from symptom-focused prescribing toward integrated, mechanism-informed care. Historically, neuropathic pain management relied heavily on oral medications, with treatment selection often based on trial-and-error. Current practice is shifting toward individualized regimens that consider pain phenotype, comorbidities, renal and hepatic function, mental health status, drug interactions, frailty, and patient-reported outcomes. This transformation supports more precise use of anticonvulsants, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, topical lidocaine or capsaicin, and interventional options.

A second shift is the growing priority of opioid stewardship. Public health authorities and clinical societies have highlighted the limited long-term role of opioids in many chronic non-cancer pain conditions and the risks of dependence, overdose, constipation, cognitive impairment, and falls. As a result, healthcare providers are expanding non-opioid neuropathic pain therapies, multimodal rehabilitation, behavioral pain strategies, and device-based approaches such as spinal cord stimulation and peripheral nerve stimulation for selected refractory cases.

A third transformation is occurring through earlier screening and prevention. Diabetes care models increasingly include foot examinations, neuropathy screening, glycemic management, cardiovascular risk reduction, and patient education to reduce complications such as ulcers and amputations. Oncology programs are also placing greater attention on chemotherapy-induced peripheral neuropathy, dose modification, survivorship care, and symptom monitoring. Together, these shifts are moving the industry toward longitudinal nerve pain management that prioritizes function, safety, adherence, and quality of life.

Cumulative Impact of Artificial Intelligence on Neuropathy Pain Treatment

Artificial intelligence is becoming a cumulative force across neuropathy pain treatment by improving detection, stratification, monitoring, and therapeutic decision support. In clinical settings, AI-enabled analytics can support identification of patients at higher risk for diabetic neuropathy, painful neuropathy, medication intolerance, falls, depression, or poor adherence by analyzing electronic health records, laboratory data, prescription patterns, comorbidities, and patient-reported symptoms. This creates opportunities for earlier intervention and more proactive chronic pain management.

AI is also strengthening neuropathic pain assessment. Machine learning models applied to quantitative sensory testing, wearable sensor data, gait analysis, sleep metrics, and digital pain diaries can help capture pain variability and functional impact beyond episodic clinic visits. Natural language processing can extract neuropathy-related symptoms from clinical notes, oncology records, and primary care documentation, supporting better recognition of underdiagnosed conditions such as chemotherapy-induced peripheral neuropathy and painful diabetic neuropathy.

In therapeutic development and care delivery, AI can accelerate target discovery, optimize clinical trial recruitment, identify responder subgroups, and support personalized treatment pathways. However, responsible implementation requires validated algorithms, representative datasets, clinician oversight, transparent performance reporting, cybersecurity safeguards, and compliance with medical device, data protection, and health equity requirements. The most meaningful impact will come from AI tools that reduce diagnostic delays, improve medication selection, flag safety risks, and enhance remote management without replacing clinical judgment.

Key Regional Insights for Neuropathy Pain Treatment

Asia-Pacific is a critical region for neuropathy pain treatment due to the high and rising burden of diabetes, rapid population aging in countries such as Japan, China, and South Korea, and expanding access to specialty care in urban centers. The region also faces substantial variation in diagnosis and treatment access between metropolitan and rural settings. Growing use of diabetes screening, oncology services, and rehabilitation programs is increasing recognition of diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy, while affordability and reimbursement differences continue to shape therapy uptake.

North America demonstrates advanced adoption of multidisciplinary pain management, neuromodulation, telehealth, and opioid-sparing care pathways. The United States and Canada have extensive clinical infrastructure for diabetes management, oncology survivorship, pain medicine, podiatry, and rehabilitation, supporting broader identification of neuropathic pain. Regulatory focus on opioid risk mitigation and evidence-based prescribing continues to influence treatment patterns, increasing demand for non-opioid pharmacologic therapies, topical treatments, behavioral care, and device-based interventions for refractory pain.

Latin America is characterized by rising diabetes prevalence, expanding private healthcare access, and growing awareness of chronic nerve pain among primary care and specialist providers. Brazil and Mexico are central to regional demand due to their large patient populations and evolving chronic disease programs. However, disparities in healthcare access, specialist availability, and reimbursement can limit timely diagnosis and continuity of neuropathy pain treatment, especially outside major cities.

Europe benefits from strong clinical guideline adoption, broad-based healthcare coverage in many countries, and established pain, neurology, endocrinology, and oncology care networks. The region emphasizes evidence-based use of neuropathic pain medications, rehabilitation, and careful opioid governance. Western European countries often lead in structured pain pathways and digital health integration, while parts of Eastern Europe continue to improve access to specialist diagnostics and advanced interventions.

The Middle East is experiencing growing demand for neuropathy pain treatment due to high diabetes prevalence in several countries, increasing obesity-related metabolic disease, and expanding tertiary healthcare infrastructure. Gulf countries are investing in specialty clinics, digital health, and chronic disease management, supporting earlier recognition of diabetic neuropathy and related complications. Access remains uneven across the broader region, with affordability, workforce distribution, and conflict-related health system disruption affecting care continuity.

Africa faces a dual challenge of increasing noncommunicable diseases and persistent resource constraints. Diabetes-related neuropathy, HIV-associated neuropathy, nutritional deficiencies, infectious disease complications, and treatment-related neuropathies contribute to regional disease burden. Diagnosis is often delayed due to limited specialist access, constrained pain management resources, and uneven availability of essential medicines. Strengthening primary care screening, affordable treatment access, diabetes control, and community-level education is central to improving outcomes across the continent.

Key Group Insights for Neuropathy Pain Treatment

ASEAN countries are seeing growing demand for neuropathy pain treatment as diabetes, aging, cancer care expansion, and urban lifestyle-related metabolic disorders increase the burden of nerve pain. Regional priorities include strengthening primary care screening, improving affordability of essential neuropathic pain medicines, integrating rehabilitation, and expanding specialist referral networks. Differences in reimbursement, healthcare infrastructure, and rural access create varied treatment adoption across member states.

The GCC represents a high-priority group due to elevated rates of diabetes and obesity, strong investment in healthcare modernization, and expanding digital health capabilities. Chronic disease management programs, endocrinology services, and tertiary care centers are central to improving diagnosis of diabetic peripheral neuropathy. The GCC's policy focus on preventive care and health system digitization supports adoption of remote monitoring, patient education, and integrated pain care.

The European Union benefits from harmonized regulatory standards, strong pharmacovigilance frameworks, and broad use of clinical guidelines for neuropathic pain. EU health systems increasingly emphasize opioid stewardship, health technology assessment, patient-reported outcomes, and equitable access to evidence-based therapies. Cross-border research collaboration and digital health regulation are supporting more structured approaches to chronic pain care and real-world evidence generation.

BRICS countries collectively represent a large and diverse neuropathy pain treatment environment shaped by substantial diabetes burden, expanding hospital networks, and uneven access to specialist pain services. China, India, Brazil, Russia, and South Africa each face distinct challenges related to affordability, primary care capacity, and regional disparities. Their scale makes prevention, early screening, and low-cost evidence-based treatment pathways particularly important.

The G7 countries generally have mature healthcare systems, established clinical guidelines, advanced pain medicine capabilities, and growing adoption of digital health tools. Aging populations, diabetes, cancer survivorship, and chronic pain policy reforms are key drivers of neuropathy pain treatment demand. These countries are also more likely to integrate real-world evidence, pharmacovigilance, and patient-centered outcomes into decision-making.

NATO member countries overlap significantly with advanced healthcare systems in North America and Europe, where chronic pain management, rehabilitation, military medicine, and trauma-related neuropathy are relevant considerations. Service-related nerve injuries, musculoskeletal trauma, and post-surgical neuropathic pain contribute to treatment needs, while coordinated medical standards and rehabilitation systems support structured approaches to functional recovery and long-term pain management.

Key Country Insights for Neuropathy Pain Treatment

The United States has a highly developed neuropathy pain treatment ecosystem shaped by a large diabetes population, advanced pain medicine infrastructure, oncology survivorship programs, and strong opioid stewardship policies. Clinical practice increasingly favors non-opioid medications, topical agents, behavioral interventions, physical therapy, and neuromodulation for selected refractory cases. Canada follows similar evidence-based approaches, supported by public healthcare coverage and national attention to chronic pain, though access to multidisciplinary pain clinics can vary by province and geography.

Mexico and Brazil are central Latin American countries for neuropathy pain treatment because of their large populations and growing burden of diabetes and metabolic disease. Mexico faces increasing demand for diabetic neuropathy screening and treatment across public and private systems, while Brazil benefits from expanding specialty care in major cities and broad public health infrastructure. In both countries, access gaps, affordability, and specialist availability influence timely diagnosis and treatment adherence.

The United Kingdom emphasizes guideline-based neuropathic pain management within a structured healthcare system, with strong focus on medication review, functional outcomes, and opioid risk reduction. Germany has advanced pain medicine, neurology, diabetes care, and rehabilitation services, supporting multidisciplinary treatment pathways. France maintains strong specialist care and pharmacovigilance systems, while Italy and Spain combine aging populations, high chronic disease needs, and established public health systems that support broad access to neuropathic pain treatment. Russia has significant demand related to diabetes, aging, and neurological disorders, with treatment access varying across regions and between urban and rural healthcare settings.

China faces a major neuropathy pain treatment challenge due to its large diabetes population, aging demographics, and expanding oncology services. Urban hospitals increasingly provide advanced diagnostics and pain care, while primary care capacity building remains important for early detection. India has rising diabetes prevalence and a large need for affordable peripheral neuropathy treatment, with opportunities centered on screening, generic medicines, telemedicine, and clinician education. Japan's super-aged population and mature healthcare system drive demand for safe, tolerable nerve pain therapies, fall-risk reduction, and integrated geriatric pain management. Australia has strong clinical governance and chronic disease programs, with attention to rural access and telehealth-enabled pain care. South Korea combines advanced healthcare infrastructure, digital health adoption, and growing diabetes and oncology survivorship needs, supporting increased recognition and treatment of neuropathic pain.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-based, opioid-sparing neuropathy pain treatment strategies that align with clinical guidelines and payer expectations. Product and service portfolios should address the full continuum of care, including early screening, symptom assessment, pharmacologic therapy, topical treatment, digital monitoring, rehabilitation, behavioral health, and interventional care for refractory patients.

A key recommendation is to invest in patient stratification. Neuropathic pain is heterogeneous, and treatment response varies by etiology, pain phenotype, comorbidities, age, concomitant medications, and psychosocial factors. Healthcare organizations should support validated assessment tools, patient-reported outcome measures, and real-world evidence programs that clarify which patients benefit from specific interventions.

Stakeholders should also strengthen clinician education in primary care, endocrinology, oncology, neurology, podiatry, and pain medicine. Earlier diagnosis of diabetic peripheral neuropathy, chemotherapy-induced peripheral neuropathy, and postherpetic neuralgia can reduce complications and improve quality of life. Educational initiatives should emphasize safe prescribing, titration, adverse-effect management, medication adherence, foot care, and referral criteria.

Digital health and AI initiatives should be pursued cautiously but proactively. Remote pain diaries, wearable-enabled functional monitoring, telehealth follow-up, and AI-supported risk identification can improve continuity of care, particularly for chronic neuropathy patients who require long-term monitoring. Solutions must be clinically validated, interoperable, privacy-compliant, and designed to reduce, not increase, workflow burden.

Finally, industry leaders should tailor access strategies to regional realities. High-income settings may prioritize advanced neuromodulation, digital therapeutics, and integrated multidisciplinary care, while emerging settings require affordable medicines, primary care screening, simplified treatment protocols, and scalable education programs. Across all settings, success depends on demonstrating improved pain relief, function, safety, adherence, and patient quality of life.

Research Methodology

The research methodology for assessing the neuropathy pain treatment landscape is grounded in verified secondary research, clinical evidence review, regulatory analysis, and structured interpretation of healthcare trends. Sources considered include peer-reviewed medical literature, clinical practice guidelines, public health agency publications, regulatory documents, disease burden databases, pharmacovigilance resources, and healthcare policy references relevant to neuropathic pain, diabetic neuropathy, postherpetic neuralgia, chemotherapy-induced peripheral neuropathy, and chronic pain management.

The methodology evaluates treatment modalities across pharmacologic, topical, interventional, device-based, rehabilitative, behavioral, and digital care categories. Evidence is assessed based on clinical relevance, safety profile, guideline support, patient outcomes, real-world applicability, and regional healthcare access considerations. Particular attention is given to opioid stewardship, non-opioid pain management, patient-reported outcomes, comorbidity management, and multidisciplinary care pathways.

Regional, group, and country insights are developed by synthesizing publicly available indicators related to diabetes burden, aging demographics, oncology survivorship, healthcare infrastructure, reimbursement environment, regulatory maturity, digital health adoption, and specialist access. The analysis avoids unsupported assumptions and excludes market sizing, market share, and forecasting. Findings are structured to support strategic decision-making for stakeholders involved in neuropathy pain treatment, chronic pain care, medical technology, digital health, and healthcare delivery.

Conclusion

Neuropathy pain treatment is evolving from generalized symptom control toward safer, more personalized, and multidisciplinary care. The field is being reshaped by the growing burden of diabetes and cancer survivorship, greater recognition of chronic nerve pain, stricter opioid stewardship, advances in neuromodulation, and the emergence of AI-enabled assessment and remote monitoring. Across regions, the most urgent needs include earlier diagnosis, broader access to evidence-based therapies, better patient education, and improved long-term treatment adherence.

High-income healthcare systems are advancing integrated pain pathways, digital health tools, and specialty interventions, while emerging healthcare systems are focused on affordable access, primary care capacity, and scalable screening programs. Regional and country-level differences in reimbursement, infrastructure, clinical workforce, and chronic disease management will continue to shape adoption patterns.

For industry leaders, the strongest strategic direction is clear: deliver clinically validated neuropathy pain solutions that improve pain relief, function, safety, and quality of life while reducing treatment burden and avoidable complications. Organizations that combine evidence-based therapy, patient-centered care, responsible AI, and access-focused implementation will be best positioned to address the expanding global need for effective neuropathic pain management.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Neuropathy Pain Treatment Market, by Treatment Type

• 7.1. Introduction
• 7.2. Complementary
  • 7.2.1. Herbal Supplements
  • 7.2.2. Mind Body Techniques
• 7.3. Device
  • 7.3.1. Neuromodulation
  • 7.3.2. TENS
• 7.4. Drug
  • 7.4.1. Analgesics
    • 7.4.1.1. Non-Opioids
    • 7.4.1.2. Opioids
  • 7.4.2. Anticonvulsants
  • 7.4.3. Antidepressants
  • 7.4.4. Topical Agents
    • 7.4.4.1. Capsaicin
    • 7.4.4.2. Lidocaine
• 7.5. Therapy
  • 7.5.1. Acupuncture
  • 7.5.2. Massage Therapy
  • 7.5.3. Physical Therapy

8. Neuropathy Pain Treatment Market, by Route Of Administration

• 8.1. Introduction
• 8.2. Injectable
  • 8.2.1. Intravenous
  • 8.2.2. Subcutaneous
• 8.3. Oral
  • 8.3.1. Capsules
  • 8.3.2. Tablets
• 8.4. Topical
  • 8.4.1. Creams
  • 8.4.2. Gels
• 8.5. Transdermal

9. Neuropathy Pain Treatment Market, by Indication

• 9.1. Introduction
• 9.2. Central Neuropathic Pain
  • 9.2.1. Spinal Cord Injury Pain
  • 9.2.2. Post-Stroke Neuropathic Pain
• 9.3. Peripheral Neuropathy

10. Neuropathy Pain Treatment Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacy
• 10.3. Online Pharmacy
• 10.4. Retail Pharmacy
• 10.5. Specialty Clinic

11. Neuropathy Pain Treatment Market, by End User

• 11.1. Introduction
• 11.2. Ambulatory Care
• 11.3. Clinic
• 11.4. Home Care
• 11.5. Hospital

12. Neuropathy Pain Treatment Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Neuropathy Pain Treatment Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Neuropathy Pain Treatment Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. AbbVie Inc.
• 16.3. Amgen Inc.
• 16.4. Astellas Pharma Inc.
• 16.5. AstraZeneca PLC
• 16.6. Aurobindo Pharma Limited
• 16.7. Baxter International Inc.
• 16.8. Bayer AG
• 16.9. Biogen Inc.
• 16.10. Boehringer Ingelheim International GmbH
• 16.11. Boston Scientific Corporation
• 16.12. Bristol Myers Squibb Company
• 16.13. DAIICHI SANKYO COMPANY, LIMITED
• 16.14. Dr. Reddy's Laboratories Ltd.
• 16.15. Eli Lilly and Company
• 16.16. Endo International PLC
• 16.17. GlaxoSmithKline PLC
• 16.18. H. Lundbeck A/S
• 16.19. Johnson and Johnson Services, Inc.
• 16.20. Medtronic PLC
• 16.21. NeuroMetrix, Inc.
• 16.22. Nevro Corporation
• 16.23. Novartis AG
• 16.24. Pfizer Inc.
• 16.25. Sun Pharmaceutical Industries Limited